Phenotypic Assays and Sequencing Are Less Sensitive Than Point Mutation Assays for Detection of Resistance in Mixed HIV-1 Genotypic Populations
about
Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infectionDeep sequencing of HIV-1 near full-length proviral genomes identifies high rates of BF1 recombinants including two novel circulating recombinant forms (CRF) 70_BF1 and a disseminating 71_BF1 among blood donors in Pernambuco, BrazilEnhanced detection of viral diversity using partial and near full-length genomes of human immunodeficiency virus Type 1 provirus deep sequencing data from recently infected donors at four blood centers in Brazil.High-resolution quantification of hepatitis C virus genome-wide mutation load and its correlation with the outcome of peginterferon-alpha2a and ribavirin combination therapyBiomarker discovery using targeted maximum-likelihood estimation: application to the treatment of antiretroviral-resistant HIV infectionCharacterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencingCharacterization of the Drug Resistance Profiles of Patients Infected with CRF07_BC Using Phenotypic Assay and Ultra-Deep Pyrosequencing.Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus.Theoretical and experimental assessment of degenerate primer tagging in ultra-deep applications of next-generation sequencing.The HIV-1 transmission bottleneck.Trofile HIV co-receptor usage assay.Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in antiretroviral-naive HIV patients in Campania, Italy.Dual-priming oligonucleotide-based multiplex PCR for the detection of Helicobacter pylori and determination of clarithromycin resistance with gastric biopsy specimens.Merkel cell polyomavirus DNA detection in lesional and nonlesional skin from patients with Merkel cell carcinoma or other skin diseases.
P2860
Q28478459-7B98BBE6-76E9-4D5A-89E5-E06C216D085AQ28544988-56BB0258-8345-4CD0-95F5-9C4DA0D60E8EQ30870822-C56DFB7C-3A07-4FDB-ADB3-3B75AA87CC97Q33784107-0DEC1AAA-6602-4E89-856B-D4D3423A1BE1Q33938373-B50A46AA-BAE3-47DC-847A-6FB8AD2689CBQ34567556-C47B6CA1-A796-4BBB-B6E1-71FC7385B45CQ36255602-E46A1544-9FA6-4683-8110-D4EE16B509C3Q41284477-3AC43F16-3076-46FE-A2F8-84572E611CF2Q42219806-73CFCE78-31CE-4ED3-AAD3-E4E42FAF05BAQ42314454-930D3780-7BC9-455B-9B44-E1EF2CB3B7A6Q44470116-4C498F82-D545-4251-878F-EEC85B1921E0Q45257444-C4E268CE-A4C3-402E-9F46-E7E887BB0990Q46134248-1201DF36-A2EC-4E0E-AE21-320578BC1424Q54469450-3FA73DA3-532B-4CC2-B8BC-525372EDB7A0
P2860
Phenotypic Assays and Sequencing Are Less Sensitive Than Point Mutation Assays for Detection of Resistance in Mixed HIV-1 Genotypic Populations
description
article
@en
im Oktober 1999 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 1999
@uk
name
Phenotypic Assays and Sequenci ...... ed HIV-1 Genotypic Populations
@en
Phenotypic Assays and Sequenci ...... ed HIV-1 Genotypic Populations
@nl
type
label
Phenotypic Assays and Sequenci ...... ed HIV-1 Genotypic Populations
@en
Phenotypic Assays and Sequenci ...... ed HIV-1 Genotypic Populations
@nl
prefLabel
Phenotypic Assays and Sequenci ...... ed HIV-1 Genotypic Populations
@en
Phenotypic Assays and Sequenci ...... ed HIV-1 Genotypic Populations
@nl
P2093
P1476
Phenotypic Assays and Sequenci ...... ed HIV-1 Genotypic Populations
@en
P2093
E. De Clercq
E. Van Wijngaerden
J. Desmyter
J.-C. Schmit
K. Van Laethem
K. Van Vaerenbergh
L. Stuyver
M. Van Ranst
M. Witvrouw
P. Hermans
P356
10.1097/00126334-199910010-00001
P407
P577
1999-10-01T00:00:00Z